Pfizer (NYSE:PFE)

Medicine pills

Short Sellers Increase Bets in Major Pharma

The short interest data have been released for the January 29 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
logo aa

The 6 Most Shorted NYSE Stocks: Short Sellers Pile on Alcoa, Freeport-McMoRan Again

Among the six most heavily shorted stocks traded on the New York Stock Exchange, short sellers continued to pile on Alcoa and Freeport-McMoRan between the January 15 and January 29 ...
Read Full Story »
Pfizer

Why Merrill Lynch Sees Big Upside in Pfizer (and Even More With Allergan)

Pfizer Inc. (NYSE: PFE) offers a compelling valuation, an attractive dividend yield and good pipeline optionality. This is in part due to its merger with Allergan PLC (NYSE: AGN), which ...
Read Full Story »
buy sell

Top Analyst Upgrades and Downgrades: Apple, Freeport-McMoRan, Kinross Gold, Pfizer, Plains All American, Salesforce, Tesla, Yelp and More

Stocks were getting pounded on Tuesday. The selling pressure seems to not have an end in 2016, even after investors successfully bought every dip for over four years. It still ...
Read Full Story »
Prescription drugs

4 Big Dividend Pharmaceutical Stocks to Buy That Are Very Cheap Now

If you ever want to look for value in a sector in the stock market, then when you see Congress calling in some of the top companies to scold them ...
Read Full Story »
Medicine pills

How Analysts View Pfizer and Merck After Earnings

Pfizer Inc. (NYSE: PFE) and Merck & Co. Inc. (NYSE: MRK) released their most recent earnings reports last week. As a result, analysts weighed in on both of these pharmaceutical ...
Read Full Story »
buy now

Merrill Lynch Has 4 Very Oversold Blue Chip Dividend Stocks to Buy Now

Needless to say, the stock market can be a very cruel mistress. Companies can report great numbers, but if the guidance is light? Look out! So what are patient long-term ...
Read Full Story »
Medicine pills

Investors OK With Pfizer Earnings, Not OK With Guidance

Pfizer Inc. (NYSE: PFE) reported fourth-quarter and full-year 2015 results before markets opened Tuesday. The company reported quarterly adjusted diluted earnings per share (EPS) of $0.53 and revenues of $14.05 ...
Read Full Story »
coins

What to Expect From Pfizer Earnings

Pfizer Inc. (NYSE: PFE) is scheduled to report its fourth-quarter financial results before the markets open on Tuesday. The consensus estimates from Thomson Reuters are $0.52 in earnings per share ...
Read Full Story »
Medicine pills

Top 3 Dow Earnings for the Coming Week

Earnings season for the fourth quarter of last year has now moved into February, and 24/7 Wall St. has put together a preview of the three Dow Jones Industrial Average ...
Read Full Story »
crash

5 Dow Stocks Getting Slammed in 2016 Have Not Even Reported Earnings Yet

2016 has not seen a good start to the year for investors. There are many positives, but the negatives are still winning and caution is in the air. Only six ...
Read Full Story »
Verizon logo

4 Out-Of-Favor Large-Cap Blue-Chip Dividend Stocks to Buy Now

Needless to say, the stock market can be a very cruel mistress. Companies can report great numbers, but if the guidance is light? Look out! So what are patient long-term ...
Read Full Story »
Medicine pills

Short Sellers Become More Selective on Major Pharma

The short interest data have been released for the January 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
logo aa

The 6 Most Shorted NYSE Stocks: Short Sellers Pile on Alcoa, Freeport-McMoRan

As the markets tanked at the beginning of 2016, what were the short sellers up to? Perhaps not surprisingly, short interest was on the rise for most of the top ...
Read Full Story »
Pfizer

Deutsche Bank Has 4 Play-It-Safe Stocks to Buy for Volatile Markets

You saw it Friday. Everything was hunky-dory, for at least one day. More volatility means more nervousness, and perhaps sleepless nights. Brave investors know that the market is getting cheap, ...
Read Full Story »